Developing new vaccines to combat antimicrobial resistant infections
Deciphering the amine/acetylation code of PNAG through comprehensive libraries of synthetic oligosaccharides for effective anti-microbial vaccines
This study is working on new vaccines to help protect people from infections caused by germs that don't respond to regular antibiotics, by focusing on a specific part of these germs that can help boost the immune system's response.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-11049361 on NIH RePORTER |
What this research studies
This research focuses on creating innovative vaccines to prevent infections caused by antimicrobial resistant microbes. It investigates a specific target called Poly-β-(1−6)-N-acetylglucosamine (PNAG), which is found on the surface of many harmful pathogens. The team will synthesize a variety of PNAG structures with different chemical modifications to understand how these variations affect the immune response. By linking these PNAG structures to a strong immunogenic carrier, the research aims to enhance the effectiveness of the vaccines in generating protective immunity.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of infections caused by antimicrobial resistant bacteria.
Not a fit: Patients who are not at risk for infections or those who do not respond to vaccines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective vaccines that protect against infections from antibiotic-resistant pathogens.
How similar studies have performed: Other research has shown promise in developing vaccines targeting similar virulence factors, indicating potential success for this approach.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Huang, Xuefei — Michigan State University
- Study coordinator: Huang, Xuefei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.